WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility

WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility

WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has received the License of Manufacturing Permit from German health authorities for its drug product facility (DP7) in Leverkusen, Germany. The permit successfully demonstrates for the first time that Premier Quality together with Record Speed WuXi Biologics consistently delivered in China can also be applied in global countries.

Bioresorbable Electronic Medicine

Bioresorbable Electronic Medicine

The scientists envision that such transient engineered technologies one day could complement or replace pharmaceutical treatments for a variety of medical conditions in humans. This type of technology, which the researchers refer to as a “bioresorbable electronic medicine,” provides therapy and treatment over a clinically relevant period of time and directly at the site where it’s needed, thereby reducing side effects or risks associated with conventional, permanent implants.

Biomanufacturing Plant Is First Of It’s Kind In The United States

Biomanufacturing Plant Is First Of It’s Kind In The United States

A next-generation biomanufacturing plant incorporates multiple innovative technologies into a single facility, and therefore is built in half the construction time with approximately one half of the operating cost of a traditional plant. The next-generation biomanufacturing plant require a smaller manufacturing footprint and offer greater environmental benefits, including reduced consumption of water and energy and lower levels of carbon emissions.